In South Korea, has recorded 51 cases COVID-19

South Korea recorded 51 new cases of coronavirus infection COVID-19 per day, the total number of infected people has increased to 12 850, recovered 11 613 people, said the organization of the Centers for control and disease prevention (KCDC) under the Ministry of health.

The whole of June in South Korea, all new local clusters COVID-19 and growth in the number of imported cases caused daily periodic jump in the number of infected. On 20 June, it reached 67, and 22 June – 17 people. The average daily number of new infected in the country is held in the corridor of 30-60 people.

According to KCDC, 36 of the number of new cases are local in origin and 15 imported from abroad. 16 cases were reported in Gyeonggi province, 12 in Gwangju, another nine in Seoul, and the rest across the country. Five infected revealed at the quarantine inspection.

For the past day hospital discharged 76 people, the total number recovered up to 11 613, which is 90.4 percent. The number of victims has reached 282 people. Only South Korea checked for coronavirus almost 1.28 million people.

More than 5.2 thousand people among all the infected are connected with the sect of "Sinchonri". At least 1598 cases were brought from abroad, of which about 77% of Korean citizens. At the quarantine inspection even if entry into the country has identified in total 729 infected.

As reported by KCDC, Wednesday, South Korea began to implement the purchase of the preparation "Ramdevpir", an import permit which was issued by the Ministry of security of food and drug administration of the ROK on June 3, and supply contracts are concluded on 29 June. Hospitals will use the drug to treat patients with coronavirus infection in a serious condition who develop pneumonia and lack of oxygen in the blood.

It is reported that up to July 7 to provide the hospital with the drug will be free of charge, and from July 8, will begin negotiations on price.

Antiviral drug "Ramdevpir" was urgently approved may 1, 2020 in the United States for the treatment of COVID-19. At the time it was developed in the framework of the fight against Ebola, but not managed to prove its effectiveness. He later showed efficacy in the treatment of infections SARS and MERS. The drug produces an American biopharmaceutical company, Gilead Sciences. Clinical trials are currently underway by an international panel of scientists on patients with severe COVID-19.

Relevant data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.